

1743

<b>TRANSMITTAL LETTER</b> (General - Patent Pending)		Docket No. 10425	
In Re Application Of: Michael BELL et al.			
Serial No. 09/991,001	Filing Date November 14, 2001	Examiner TC 1700	Group Art Unit 1743

Title: **METHOD AND APPARATUS FOR MULTIPLEX FLOW CYTOMETRY ANALYSIS FROM SAMPLES**

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is: **SUPPLEMENTAL TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**INFORMATION DISCLOSURE CITATION; REFERENCES**

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **19-2090** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

  
Signature

Denton L. Anderson  
Registration No. 30,153  
SHELDON & MAK  
225 S. Lake Ave., 9th Floor  
Pasadena, CA 91101

626-796-4000

Dated: July 10, 2002

I certify that this document and fee is being deposited on July 10, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Signature of Person Mailing Correspondence

Jennifer Hargis

Typed or Printed Name of Person Mailing Correspondence

JGS/DLA/jjh

cc:

Supplemental

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))		Docket No. 14025	
In Re Application Of: <b>Michael L. BELL et al.</b>			
Serial No. 09/991,001	Filing Date November 14, 2001	Examiner	Group Art Unit 1743
Title: <b>METHOD AND APPARATUS FOR MULTIPLEX FLOW CYTOMETRY ANALYSIS FROM BODILY FLUID SAMPLES</b>			
Address to: Assistant Commissioner for Patents Washington, D.C. 20231			
<b>37 CFR 1.97(b)</b>			
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.			
<b>37 CFR 1.97(c)</b>			
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:			
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);			
OR			
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).			

RECEIVED  
AUG 07 2002  
TC 1700

RECEIVED

AUG 30 2002

TECH CENTER 1600/2900

RECEIVED  
AUG 13 2002  
1700 MAIL ROOM

RECEIVED  
JUL 24 2002  
TECHNOLOGY CENTER 1700

*Supplemental*  
**INFORMATION DISCLOSURE CITATION**  
*(Use several sheets if necessary)*

Docket Number (Optional)

14025

Application Number

09/991,001

Applicant(s)

Michael L. BELL et al.

Filing Date

November 14, 2001

Group Art Unit

1743

\*EXAMINER

INITIAL

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

Angew, Chem, Int. Ed. Engl. 30 (1991) No. 12; pgs. 1646-1648 "A New Chromogenic B-Galactosidase Substrate: 7-B-D-Galactopyranosyloxy-9, 9-dimethyl-9H-acridin-2-one, Paul F. Corey, Robert W. Trimmer, and William G. Biddlecom

Tietz Textbook of Clinical Chemistry, Chapter 22, pgs. 652-721

Clin Chim Acta 1976 Jul. 15; 70(2): 333-336; An artefact in lactate dehydrogenase isoenzyme patterns, assayed by fluorescence, occurring in the serum of patients with end-stage renal disease requiring maintenance haemodialysis. McKenzie D. Henderson AR

J Biochem (Tokyo) 1983 Apr.; 93(4): 1055-1060; Preparation of a new fluorogenic substrate of alpha-amylases and a simple alpha-amylase assay by HPLC; Omichi K., Ikenaka T.

Clin Chim Acta 1984 Apr. 13; 138(2): 197-203; Differential assay of human pancreatic and salivary alpha-amylases in serum using a new fluorogenic substrate; Omichi K. Ikenaka T.

J. Biochem (Tokyo) 1986 Jan.; 99(1): 291-294; Fluorometric rate assay of alpha-amylase using an intramolecularly-quenched fluorescent substrate (FG5P). Omichi K., Ikenaka T.

J Chromatogr 1987 Aug. 7; 419: 51-60; Liquid chromatographic assay of the relative activities of serum pancreatic and salivary alpha-amylase using reductively pyridylaminated maltopentaose as a fluorescent substrate. Honda S., Ohmura T., Begawa Y., Minematsu T. Kakehi K.

Clin Chem 1975 Nov.; 21 (12) 1788-1790; Fluorometric method for measuring serum lipase activity. Tietz B., Guilbault GC

Clin Chem 1986 Aug.; 32(8): 1532-1536; Fluorometric assay for pancreatic lipase; Salvayre R., Negre A., Radomski J., Douste-Blazy L.

Biochim Biophys Acta 1988 Nov. 25; 963(2): 340-348; Hydrolysis of fluorescent pyrenetriacylglycerols by lipases from human stomach and gastric juice; Negre A., Salvayre R., Dousset N., Rogalle P., Dang QQ, Douste-Blazy L.

Anal Chem 1992 Jan. 15; 64(2): 181-186; Determination of human serum alcohol dehydrogenase using isozyme-specific fluorescent substrates; Wierzchowski J., Holmquist B., Vallee BL.

J Pept Sci 1998 Apr.; 4(2): 83-91; Inhibition of cruzipain visualized in a fluorescence quenched solid-phase inhibitor library assay. D-amino acid inhibitors for cruzipain, cathepsin B and cathepsin L.; Meldal M., Svendsen IB, Juliano L., Juliano MA, Nery Ed, Scharfstein J.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Supplemental*  
**INFORMATION DISCLOSURE CITATION**  
*(Use several sheets if necessary)*

Docket Number (Optional)

14025

Application Number

09/991,001

Applicant(s)

Michael L. BELL et al.

Filing Date

November 14, 2001

Group Art Unit

1743

\*EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Proc Natl Acad Sci USA 1994 Apr. 12; 91(8): 3314-3318; Portion-mixing peptide libraries of quenched fluorogenic substrates for complete subsite mapping of endoprotease specificity; Meldal M., Svendsen I., Breddam K., Auzanneau F.

Methods Mol Biol 1998; 87: 51-57; Introduction to combinatorial solid-phase assays for enzyme activity and inhibition; Meldal M.

Anal Biochem 1991 Apr.; 194(1): 185-191; A solid-phase assay for beta-1,4-galactosyltransferase activity in human serum using recombinant aequorin; Zatta PF, Nyame K., Cormier MJ, Mattox SA, Prieto PA, Smith DF, Cummings RD

Appl Biochem Biotechnol 1996 Feb.; 56(2): 155-167; Immobilized glucose-6-phosphate dehydrogenase as a substrate for solubilized epidermal growth factor receptor tyrosine kinase. A convenient microtiter plate assay system; Cheng CH, Hui ST.

Clin Chem 1975 Nov.; 21(12): 1791-1794; Fluorometric assay of serum acid or alkaline phosphatase, either in solution or on a semisolid surface; Rietz B., Guilbault GG.

Clin Chim Acta 1980 Oct. 23; 107(1-2): 21-26; A new fluorimetric method for the determination of gamma-glutamyltransferase activity in blood serum; Prusak E., Siewinski M., Szewczuk A.

Clin Chim Acta 1982 June 3; 121(3): 291-300; Localization of gamma-glutamyl transferase on polyacrylamide gels using gamma-glutamyl-p-nitroanilide as substrate; Selvaraj P., Balasubramanian KA

Ann Clin Biochem 1985 Jul.; 22(Pt 4): 376-380; Electrophoretic studies of serum gamma-glutamyl transferase from patients with hepatoma; Hammond KD, Gravenor MJ, Piesas D

Spatial and Spectral Imaging of Single Micron-Sized Solvent Cast Fluorescent Plasticized Poly(vinyl chloride) Optode particles; Ioannis Tsagkatakis, Shane Peper and Eric Bakker; Department of Chemistry, Auburn University, Auburn, Alabama 36849; Submitted to BCI on May 22, 2000 to be published in Analytical Chemistry; pgs 1-4, Figures 1, 3, 4, 5 and 6

Cytometry 25: 374-380 (1996); Flow Cytometric Analysis of Gelatinase B (MMP-9) Activity using immobilized fluorescent substrate on microspheres; Yves St-Pierre, Marcel Desrosiers, Pierre Tremblay, Perre-Olivier Esteve, and Ghislain Opendakker

Proc. Natl. Acad. Sci. USA Vol. 91. pp. 3314-3318, April 1994 Chemistry; Portion-mixing peptide libraries of quenched fluorogenic substrates for complete subsite mapping of endoprotease specificity; Morten Meldal, IB Svendsen, Klaus Breddam, and France-Isabelle Auzanneau

The Journal of Biological Chemistry, Vol. 272, No. 5, Issue of January 31, pp. 2709-2713, 1997; A bifunctionalized fluorogenic tetrasaccharide as a substrate to study cellulases; Sylvie Armand, Sophie Drouillard, Martin Schulein, Bernard Henrissat, and Hughes Driguez.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUL 22 2002  
 PATENT & TRADEMARK OFFICE

Application Number	09/991,001
--------------------	------------

**Filing Date**  
**November 14, 2001**

Group Art Unit	1743
----------------	------

SUBCLASS	FILING DATE
AUG 07 2002	RE APPROPRIATE
TC 1700	RECEIVED
TECHNOLOGY CENTER 1700	JUL 24 2002
CEIVED	30 2002
TER 1600/2900	

RECEIVED  
AUG 30 2002  
CH CENTER 1600/290

RECEIVED	AUG 13 2000	TC 1700 MAIL
----------	-------------	--------------

RECEIVED	AUG 13 2000	TC 1700 MAIL
----------	-------------	--------------

**1-phase inhibitor library**  
 wendtsen, Luiz Juliano

**1-phase inhibitor library**  
 wendtsen, Luiz Juliano

**DATE CONSIDERED**

**1-phase inhibitor library**  
 wendtsen, Luiz Juliano